Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

European equities have started the week with a positive trading day, but with investors still reeling from one of the wildest ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...